New Delhi, August 2025 — India is charting its path from generic dominance to innovation leadership with the launch of the Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP)—a transformative ₹5,000 crore initiative driven by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers. Slated to begin disbursals by the end of 2025, PRIP aims to usher in a new era of original drug discovery, medical device innovation, and global competitiveness.
Funding Categories at a Glance
| Category | Eligible Entities | Maximum Support | Innovation Stage |
|---|---|---|---|
| B-I Industry–Academia Collaboration | Pharma/MedTech companies with academic partners | ₹125 crore or 35% of project cost | Ideation to commercialization (TRL 1–9) |
| B-II Lab-to-Market Transition | Pharma/MedTech companies | ₹100 crore or 35% | Early validation to commercialization (TRL 5–9) |
| B-III Emerging Innovators | MSMEs / Startups | ₹1 crore | Proof-of-concept (TRL 1–4) |
Targeted Innovation Areas
PRIP prioritizes sectors with immense potential:
- New Chemical & Biological Entities, including phytopharmaceuticals
- Complex Generics & Biosimilars
- Precision Medicine & Stem Cell Therapies
- Medical Devices & Orphan Drugs
- Antimicrobial Resistance (AMR) Solutions
Strategic Vision & Expected Impact
- Dr. Mansukh Mandaviya, Health Minister, positioned PRIP as a clarion call for “innovation-based growth,” building on India’s well-known strength in generics.
- Thought leaders foresee PRIP as a game-changer—driving an estimated ₹17,000 crore in additional R&D investments and strengthening innovation ecosystems across industry and academia.
- Central to India’s R&D leap: The scheme fosters high-end research, job creation, and bolstered self-reliance in healthcare technology while enhancing global competitiveness.
How to Apply & Engage
Organizations—including pharmaceutical and medtech firms, startups, MSMEs, and academic institutions—are invited to submit Expressions of Interest (EoI) through the official PRIP portal managed by the Department of Pharmaceuticals. Detailed operational guidelines, FAQs, and application forms are available.
📝 Information Disclaimer & Sources
Disclaimer: The information provided in this article is compiled from official government notifications, reputed news outlets, and publicly available resources. While every effort has been made to ensure accuracy, readers are advised to refer to official government websites and notifications for the most up-to-date and detailed information before making any decisions or applications.
Sources:
